Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: With increasing healthcare resource constraints, it has become important to understand the incremental cost-effectiveness of new medicines. Subcutaneous denosumab is superior to intravenous zoledronic acid (ZA) for the prevention of skeletal-related events (SREs) in patients with advanced solid tumors and bone metastases. This study sought to determine the lifetime cost-effectiveness of denosumab vs ZA in this setting, from a US managed-care perspective. METHODS: A lifetime Markov model was developed, with relative rate reductions in SREs for denosumab vs ZA derived from three pivotal Phase 3 trials involving patients with castration-resistant prostate cancer (CRPC), breast cancer, and non-small-cell lung cancer (NSCLC), and bone metastases. The real-world SRE rates in ZA-treated patients were derived from a large commercial database. SRE and treatment administration quality-adjusted life year (QALY) decrements were estimated with time-trade-off studies. SRE costs were estimated from a nationally representative commercial claims database. Drug, drug administration, and renal monitoring costs were included. Costs and QALYs were discounted at 3% annually. One-way and probabilistic sensitivity analyses were conducted. RESULTS: Across tumor types, denosumab was associated with a reduced number of SREs, increased QALYs, and increased lifetime total costs vs ZA. The costs per QALY gained for denosumab vs ZA in CRPC, breast cancer, and NSCLC were $49,405, $78,915, and $67,931, respectively, commonly considered good value in the US. Costs per SRE avoided were $8567, $13,557, and $10,513, respectively. Results were sensitive to drug costs and SRE rates. LIMITATIONS: Differences in pain severity and analgesic use favoring denosumab over ZA were not captured. Mortality was extrapolated from fitted generalized gamma function beyond the trial duration. CONCLUSION: Denosumab is a cost-effective treatment option for the prevention of SREs in patients with advanced solid tumors and bone metastases compared to ZA. The overall value of denosumab is based on superior efficacy, favorable safety, and more efficient administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A comparison of the EQ‐5D and SF‐6D across seven patient groups
Brazier, J., Roberts, J., Tsuchiya, A., & Busschbach, J. (2004) · Health Economics · doi:10.1002/hec.866 · Cited by 797
Rosen, L. S., Gordon, D., Tchekmedyian, N. S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., de Souza, P., Zheng, M., Urbanowitz, G., et al. (2004) · Cancer · doi:10.1002/cncr.20308 · Cited by 705
Body, J.-J., Facon, T., Coleman, R. E., Lipton, A., Geurs, F., Fan, M., Holloway, D., Peterson, M. C., & Bekker, P. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1933 · Cited by 490
Research works printed but not linked: 44
- 10.1634/theoncologist.9-90004-14 · DOI · Paper page
- Mundy GR, 2002, Nat Rev Cancer, 2, 584, 10.1038/nrc867 · DOI · Paper page
- Roodman GD, 2004, N Engl J Med, 350, 1655, 10.1056/NEJMra030831 · DOI · Paper page
- Coleman RE, 1997, Cancer, 80, 1588, 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G · DOI · Paper page
- Coleman RE, 2006, Clin Cancer Res, 12, 6243s, 10.1158/1078-0432.CCR-06-0931 · DOI · Paper page
- 10.1093/annonc/mdi122 · DOI · Paper page
- Pockett RD, 2010, Eur J Cancer Care (Engl), 19, 755, 10.1111/j.1365-2354.2009.01135.x · DOI
- Delea T, 2006, J Support Oncol, 4, 341
- Barlev A, 2010, J Manag Care Pharm, 16, 693, 10.18553/jmcp.2010.16.9.693 · DOI · Paper page
- 10.1002/cncr.23775 · DOI
- 10.1200/JCO.2005.05.116 · DOI · Paper page
- 10.1093/jnci/djh141 · DOI · Paper page
- Fizazi K, 2011, Lancet, 377, 813, 10.1016/S0140-6736(10)62344-6 · DOI · Paper page
- Stopeck AT, 2010, J Clin Oncol, 28, 5132, 10.1200/JCO.2010.29.7101 · DOI · Paper page
- Henry DH, 2011, J Clin Oncol, 29, 1125, 10.1200/JCO.2010.31.3304 · DOI · Paper page
- Lipton A, 2011, Ann Oncol, 21, viii380
- von Moos R, 2010, J Clin Oncol, 18
- Stopeck AT, 2010, J Clin Oncol, 28, 10.1200/JCO.2010.29.7101 · DOI · Paper page
- Fallowfield L, 2011, J Clin Oncol, 29
- Annemans L, 2010, Drug Dev Res, 71, 457, 10.1002/ddr.20420 · doi:10.1002/ddr.20420
- Coleman RE, 2011, Nat Rev Urol, 8, 296, 10.1038/nrurol.2011.63 · DOI
- 10.1200/JCO.2010.33.5596 · DOI
- Xie J, 2011, J Manag Care Pharm, 17, 621, 10.18553/jmcp.2011.17.8.621 · DOI
- Rader M, 2012, J Manag Care Pharm, 18, 74, 10.18553/jmcp.2012.18.1.74 · DOI
- Gold MR, 1996, Cost-effectiveness in health and medicine, 10.1093/oso/9780195108248.001.0001 · DOI · Paper page
- Botteman M, 2006, Ann Oncol, 17, 1072, 10.1093/annonc/mdl093 · DOI
- McKeage K, 2008, Pharmacoeconomics, 26, 251, 10.2165/00019053-200826030-00007 · DOI
- Saad F, 2002, Clin Prostate Cancer, 1, 145, 10.3816/CGC.2002.n.016 · DOI
- Matza LS, 2011, J Clin Oncol, 19
- Bell JM, 2011, Value Health, 14, A159, 10.1016/j.jval.2011.02.885 · DOI
- Sathiakumar N, 2011, Prostate Cancer Prostatic Dis, 14, 177, 10.1038/pcan.2011.7 · DOI · Paper page
- 10.1007/s005200100249 · DOI
- Oglesby A, 2009, Commun Oncol, 6, 494, 10.1016/S1548-5315(11)70357-6 · DOI
- Lage MJ, 2008, Am J Manag Care, 14, 317
- Brazier J, 1993, Qual Life Res, 2, 169, 10.1007/BF00435221 · DOI · Paper page
- Hinz A, 2006, Psychother Psychosom Med Psychol, 56, 42, 10.1055/s-2005-867061 · DOI
- Kaarlola A, 2004, Intensive Care Med, 30, 2245, 10.1007/s00134-004-2471-6 · DOI
- Stein K, 2005, Appl Health Econ Health Policy, 4, 219, 10.2165/00148365-200504040-00004 · DOI
- 10.1586/14737167.2.2.99 · DOI
- Brazier J, 2008, Pharmacoeconomics, 26, 769, 10.2165/00019053-200826090-00007 · DOI
- Chambers JD, 2010, Med Decis Making, 30, E14, 10.1177/0272989X10371134 · DOI
- Nadler E, 2006, Oncologist, 11, 90, 10.1634/theoncologist.11-2-90 · DOI · Paper page
- Lee CP, 2009, Value Health, 12, 80, 10.1111/j.1524-4733.2008.00401.x · DOI · Paper page
- 10.1097/01.ju.0000116777.94426.60 · DOI
Cited by
Lipton, A., Fizazi, K., Stopeck, A. T., Henry, D. H., Brown, J. E., Yardley, D. A., Richardson, G. E., Siena, S., Maroto, P., Clemens, M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.08.002 · Cited by 588
Self-citationMcCloskey, C., Ortega, M. T., Nair, S., Garcia, M. J., & Manevy, F. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-022-00361-3 · Cited by 66
Raje, N., Roodman, G. D., Willenbacher, W., Shimizu, K., García-Sanz, R., Terpos, E., Kennedy, L., Sabatelli, L., Intorcia, M., & Hechmati, G. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1445634 · Cited by 25
Cristino, J., Finek, J., Jandova, P., Kolek, M., Pásztor, B., Giannopoulou, C., Qian, Y., Brezina, T., & Lothgren, M. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1328423 · Cited by 16
“Most of the model inputs included in the PSAs were sampled as described in the PSA Appendix of the Stopeck et al.30 study.”
InfluentialSelf-citation
Metadata
- Authors
- Stopeck, A., Rader, M., Henry, D., Danese, M., Halperin, M., Cong, Z., Qian, Y., Dansey, R., & Chung, K.
- Venue
- Journal of Medical Economics
- Publisher
- Informa UK Limited
- Published
- 2012-03-27
- Volume
- 15
- Issue
- 4
- Pages
- 712-723
- ISSN
- 1369-6998 (ISSN-L)
- 1941-837X
- OpenAlex
- W2153087381
- Cited by
- 64
- References
- 3
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. https://app.cochat.ai/papers/10.3111/13696998.2012.675380
- The paper
- Stopeck, A., Rader, M., Henry, D., Danese, M., Halperin, M., Cong, Z., Qian, Y., Dansey, R., & Chung, K. (2012). Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. Journal of Medical Economics. https://doi.org/10.3111/13696998.2012.675380
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.